{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:18:41Z","timestamp":1782778721636,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Medications for opioid use disorder (MOUDs), including methadone, buprenorphine, and naltrexone, decrease mortality and morbidity for people with opioid use disorder (OUD). Buprenorphine and methadone have the strongest evidence base among MOUDs. Unlike methadone, buprenorphine may be prescribed in office-based settings in the U.S., including by nurse practitioners (NPs) and physician assistants (PAs) who have a federal waiver and adhere to federal patient limits. Buprenorphine is underutilized nationally, particularly in rural areas, and NPs\/PAs could help address this gap. Therefore, we sought to identify perceptions of buprenorphine efficacy and perceptions of prescribing barriers among NPs\/PAs. We also sought to compare perceived buprenorphine efficacy and perceived prescribing barriers between waivered and non-waivered NPs\/PAs, as well as to compare perceived buprenorphine efficacy to perceived naltrexone and methadone efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We disseminated an online survey to a random national sample of NPs\/PAs. We used Mann\u2013Whitney <jats:italic>U<\/jats:italic> tests to compare between waivered and non-waivered respondents. We used non-parametric Friedman tests and post-hoc Wilcoxon signed-rank tests to compare perceptions of medication types.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>240 respondents participated (6.5% response rate). Most respondents agreed buprenorphine is efficacious and believed counseling and peer support should complement buprenorphine. Buprenorphine was generally perceived as more efficacious than both naltrexone and methadone. Perceived buprenorphine efficacy and prescribing barriers differed by waiver status. Non-waivered practitioners were more likely than waivered practitioners to have concerns about buprenorphine affecting patient mix. Among waivered NPs\/PAs, key buprenorphine prescribing barriers were insurance prior authorization and detoxification access.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results suggest that different policies should target perceived barriers affecting waivered versus non-waivered NPs\/PAs. Concerns about patient mix suggest stigmatization of patients with OUD. NP\/PA education is needed about comparative medication efficaciousness, particularly regarding methadone. Even though many buprenorphine treatment patients benefits from counseling and\/or peer support groups, NPs\/PAs should be informed that such psychosocial treatment methods are not necessary for all buprenorphine patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00321-6","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T12:03:19Z","timestamp":1660046599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6369","authenticated-orcid":false,"given":"Barbara","family":"Andraka-Christou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-6120","authenticated-orcid":false,"given":"Victoria","family":"Schoebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1726-047X","authenticated-orcid":false,"given":"Jessica","family":"Buche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-1516","authenticated-orcid":false,"given":"Rebecca L.","family":"Haffajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"issue":"2","key":"321_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2): e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"321_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345. https:\/\/doi.org\/10.7326\/M17-3107.","journal-title":"Ann Intern Med"},{"key":"321_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","volume":"103","author":"RP Schwartz","year":"2013","unstructured":"Schwartz RP, Gryczynski J, O\u2019Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009. Am J Public Health. 2013;103:917\u201322. https:\/\/doi.org\/10.2105\/AJPH.2012.301049.","journal-title":"Am J Public Health"},{"issue":"2","key":"321_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.drugalcdep.2013.06.024","volume":"133","author":"D Otiashvili","year":"2013","unstructured":"Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior: outcomes of a randomized trial. Drug Alcohol Depend. 2013;133(2):376\u201382. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.06.024.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"321_CR5","first-page":"416","volume":"100","author":"D Coffa","year":"2019","unstructured":"Coffa D, Snyder H. Opioid use disorder: medical treatment options. Am Fam Phys. 2019;100(7):416.","journal-title":"Am Fam Phys"},{"key":"321_CR6","unstructured":"Drug addiction treatment Act of 2000, 21 U.S.C. \u00a7 823"},{"key":"321_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12569","author":"CHA Andrilla","year":"2021","unstructured":"Andrilla CHA, Patterson DG. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health. 2021. https:\/\/doi.org\/10.1111\/jrh.12569.","journal-title":"J Rural Health"},{"issue":"11","key":"321_CR8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/jama.2016.10542","volume":"316","author":"BD Stein","year":"2016","unstructured":"Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211\u20132. https:\/\/doi.org\/10.1001\/jama.2016.10542.","journal-title":"JAMA"},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"109089","DOI":"10.1016\/j.drugalcdep.2021.109089","volume":"228","author":"I Cabreros","year":"2021","unstructured":"Cabreros I, Griffin BA, Saloner B, Gordon AJ, Kerber R, Stein BD. Buprenorphine prescriber monthly patient caseloads: an examination of 6-year trajectories. Drug Alcohol Depend. 2021;228:109089. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109089.","journal-title":"Drug Alcohol Depend."},{"key":"321_CR10","unstructured":"Comprehensive addiction and recovery act of 2016, public law 114\u2013198, (2016)."},{"issue":"2","key":"321_CR11","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1177\/1077558718793070","volume":"77","author":"CHA Andrilla","year":"2018","unstructured":"Andrilla CHA, Patterson DG, Moore TE, Coulthard C, Larson EH. Projected contributions of nurse practitioners and physicians assistants to buprenorphine treatment services for opioid use disorder in rural areas. Med Care Res Rev. 2018;77(2):2018\u2013216. https:\/\/doi.org\/10.1177\/1077558718793070.","journal-title":"Med Care Res Rev"},{"key":"321_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108032","volume":"115","author":"SG Auty","year":"2020","unstructured":"Auty SG, Stein MD, Walley AY, Drainoni ML. Buprenorphine waiver uptake among nurse practitioners and physician assistants: the role of existing waivered prescriber supply. J Subst Abuse Treat. 2020;115: 108032. https:\/\/doi.org\/10.1016\/j.jsat.2020.108032.","journal-title":"J Subst Abuse Treat"},{"key":"321_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108083","volume":"213","author":"DR Roehler","year":"2020","unstructured":"Roehler DR, Guy GP Jr, Jones CM. Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017\u20132018: a cross-sectional study. Drug Alcohol Depend. 2020;213: 108083. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108083.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"321_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jrh.12404","volume":"36","author":"CHA Andrilla","year":"2020","unstructured":"Andrilla CHA, Jones KC, Patterson DG. Prescribing practices of nurse practitioners and physician assistants waivered to prescribe buprenorphine and the barriers they experience prescribing buprenorphine. J Rural Health. 2020;36(2):187\u201395. https:\/\/doi.org\/10.1111\/jrh.12404.","journal-title":"J Rural Health"},{"issue":"6","key":"321_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","volume":"19","author":"A Sharma","year":"2017","unstructured":"Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O\u2019Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19(6):35. https:\/\/doi.org\/10.1007\/s11920-017-0783-9.","journal-title":"Curr Psychiatry Rep."},{"key":"321_CR16","first-page":"22439","volume":"12","author":"Office of the Secretary DoHaHS","year":"2021","unstructured":"Office of the Secretary DoHaHS. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. Feder Registrar. 2021;12:22439\u201340.","journal-title":"Feder Registrar"},{"key":"321_CR17","unstructured":"Substance abuse and mental health services administration. Medications for opioid use disorder. Treatment improvement protocol (TIP) series 63, full document. 2018. https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document\/PEP20-02-01-002. Accessed 25 July 2022."},{"key":"321_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-020-00312-3","author":"RL Haffajee","year":"2020","unstructured":"Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020. https:\/\/doi.org\/10.1186\/s13011-020-00312-3.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"321_CR19","unstructured":"HHS expands access to treatment for opioid use disorder. January 14, 2021, 2021. https:\/\/www.hhs.gov\/about\/news\/2021\/01\/14\/hhs-expands-access-to-treatment-for-opioid-use-disorder.html."},{"key":"321_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08897077.2021.1903659","volume":"42","author":"B Saloner","year":"2021","unstructured":"Saloner B, Andraka Christou B, Gordon AJ, Stein BD. It will end in tiers: A strategy to include \u201cdabblers\u201d in the buprenorphine workforce after the X-waiver. Subst Abuse. 2021;42:1\u20135. https:\/\/doi.org\/10.1080\/08897077.2021.1903659.","journal-title":"Subst Abuse"},{"key":"321_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","volume":"78","author":"AS Huhn","year":"2017","unstructured":"Huhn AS, Dunn KE. Why aren\u2019t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1\u20137. https:\/\/doi.org\/10.1016\/j.jsat.2017.04.005.","journal-title":"J Subst Abuse Treat"},{"key":"321_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugpo.2017.11.021","volume":"54","author":"B Andraka-Christou","year":"2018","unstructured":"Andraka-Christou B, Capone MJ. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. Int J Drug Policy. 2018;54:9\u201317. https:\/\/doi.org\/10.1016\/j.drugpo.2017.11.021.","journal-title":"Int J Drug Policy"},{"key":"321_CR23","doi-asserted-by":"publisher","first-page":"107952","DOI":"10.1016\/j.drugalcdep.2020.107952","volume":"209","author":"G Pro","year":"2020","unstructured":"Pro G, Utter J, Haberstroh S, Baldwin JA. Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: associations moderated by state Medicaid expansion status, race\/ethnicity and gender, and year. Drug Alcohol Depend. 2020;209:107952. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107952.","journal-title":"Drug Alcohol Depend"},{"key":"321_CR24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000818","author":"AJ Ober","year":"2021","unstructured":"Ober AJ, Hunter SB, McCullough CM, et al. Opioid use disorder among clients of community mental health clinics: prevalence, characteristics, and treatment willingness. Psychiatr Serv. 2021. https:\/\/doi.org\/10.1176\/appi.ps.202000818.","journal-title":"Psychiatr Serv"},{"issue":"10","key":"321_CR25","doi-asserted-by":"publisher","first-page":"e2129409","DOI":"10.1001\/jamanetworkopen.2021.29409","volume":"4","author":"B Han","year":"2021","unstructured":"Han B, Jones CM, Einstein EB, Compton WM. Trends in and characteristics of buprenorphine misuse among adults in the US. JAMA Netw Open. 2021;4(10):e2129409. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.29409.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"321_CR26","doi-asserted-by":"publisher","first-page":"e2123019","DOI":"10.1001\/jamanetworkopen.2021.23019","volume":"4","author":"B Saloner","year":"2021","unstructured":"Saloner B, Whitley P, LaRue L, Dawson E, Huskey A. Polysubstance use among patients treated with buprenorphine from a national urine drug test database. JAMA Netw Open. 2021;4(9):e2123019. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.23019.","journal-title":"JAMA Netw Open"},{"key":"321_CR27","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","volume":"174","author":"KM Carroll","year":"2017","unstructured":"Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174:738\u201347. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16070792.","journal-title":"Am J Psychiatry"},{"key":"321_CR28","doi-asserted-by":"publisher","first-page":"108923","DOI":"10.1016\/j.drugalcdep.2021.108923","volume":"228","author":"JJ Wyse","year":"2021","unstructured":"Wyse JJ, Morasco BJ, Dougherty J, et al. (2021) Adjunct interventions to standard medical management of buprenorphine in outpatient settings: a systematic review of the evidence. Drug Alcohol Depend. 2021;228:108923. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108923.","journal-title":"Drug Alcohol Depend"},{"key":"321_CR29","unstructured":"American society of addiction medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. 2020. https:\/\/www.asam.org\/quality-care\/clinical-guidelines\/national-practice-guideline. Accessed 25 July 2022."},{"key":"321_CR30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1001\/jama.2019.0834","volume":"321","author":"J Spetz","year":"2019","unstructured":"Spetz J, Toretsky C, Chapman S, Phoenix B, Tierney M. Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA. 2019;321:1407\u20138.","journal-title":"JAMA"},{"key":"321_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/10775587211004311","author":"T Nguyen","year":"2021","unstructured":"Nguyen T, Muench U, Andraka-Christou B, Simon K, Bradford WD, Spetz J. The association between scope of practice regulations and nurse practitioner prescribing of buprenorphine after the 2016 opioid bill. Med Care Res Rev. 2021. https:\/\/doi.org\/10.1177\/10775587211004311.","journal-title":"Med Care Res Rev"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00321-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T12:14:56Z","timestamp":1660047296000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00321-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00321-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"3 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We received ethical approval from the University of Michigan Institutional Review Board for this research and respondents were provided with an explanation of research at the beginning of the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In 2017, Dr. Andraka-Christou received a research grant from Alkermes, the manufacturer of extended-release naltrexone, to develop educational online modules and a mobile application for college students with substance use disorder. None of the authors has relevant financial interests or relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, this submitted work. This article was conceived and drafted when Dr. Haffajee was employed at the RAND Corporation\u00a0and the University of Michigan, and the findings and views in this article do not necessarily reflect the official views or policy of her current employer, the U.S. Department of Health and Human Services, or the U.S. Government.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}